The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer’s disease in rodents

Glycogen synthase kinase 3 (GSK3) has been identified as a promising target for the treatment of Alzheimer’s disease (AD), where abnormal activation of this enzyme has been associated with hyperphosphorylation of tau proteins. This study describes the effects of the selective GSK3 inhibitor, SAR5022...

Descripción completa

Detalles Bibliográficos
Autores principales: Griebel, Guy, Stemmelin, Jeanne, Lopez-Grancha, Mati, Boulay, Denis, Boquet, Gerald, Slowinski, Franck, Pichat, Philippe, Beeské, Sandra, Tanaka, Shinji, Mori, Akiko, Fujimura, Masatake, Eguchi, Junichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888874/
https://www.ncbi.nlm.nih.gov/pubmed/31792284
http://dx.doi.org/10.1038/s41598-019-54557-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888874/
https://www.ncbi.nlm.nih.gov/pubmed/31792284
http://dx.doi.org/10.1038/s41598-019-54557-5

Ejemplares similares